Budesonide to prevent serious diarrhea after stem cell transplant
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests whether budesonide can lower the chance of moderate-to-severe diarrhea in people with multiple myeloma who are getting an autologous stem cell transplant. It may help your comfort and reduce complications during the transplant recovery period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have multiple myeloma (or plasma cell leukemia).
- Be planning an autologous stem cell transplant using melphalan conditioning (either 200 mg/m² or 140 mg/m²).
- Be able to sign informed consent and follow study instructions.
- Have blood tests showing your liver is working well enough (bilirubin and liver enzymes within allowed limits).
- If you can become pregnant, have a negative pregnancy test or meet post-menopause or surgical sterilization rules.
- Not be taking budesonide by mouth at the time you enroll.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.